Basis: (FMP quote price / unrounded diluted TTM EPS) / explicitly dated EPS growth percent. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-09-19T00:15:51.936Z.
Calculation as of: 2026-09-19T00:15:51.936Z.
Quote observation: 2026-09-18T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 19e5010cd34a848df86eef5fa49b647d89bc6ef8f6902ab99c9afc77e7f09360
PEG RATIO
N/A
Novo Nordisk A/S
Market Cap
$192.01B
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Novo Nordisk A/S (NVO) | $192.01B | N/A |
| Gilead Sciences, Inc. (GILD)vs › | $186.37B | N/A |
| Abbott Laboratories (ABT)vs › | $177.45B | N/A |
| Amgen Inc. (AMGN)vs › | $208.14B | N/A |
| Pfizer Inc. (PFE)vs › | $157.30B | N/A |
| Danaher Corporation (DHR)vs › | $148.87B | N/A |
| Thermo Fisher Scientific Inc. (TMO)vs › | $242.09B | N/A |
| Intuitive Surgical, Inc. (ISRG)vs › | $138.95B | N/A |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $129.02B | N/A |
| Bristol-Myers Squibb Company (BMY)vs › | $128.81B | N/A |
PEG Ratio
N/A
P/E Ratio
10.7
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
